| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 58.38 | 1-year : | 68.19 |
| Resists | First : | 49.99 | Second : | 58.38 |
| Pivot price | 47.6  |
|||
| Supports | First : | 45.37 | Second : | 42.52 |
| MAs | MA(5) : | 48.3 |
MA(20) : | 47.24 |
| MA(100) : | 46.24 |
MA(250) : | 50.86  |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 82.5 |
D(3) : | 68.7 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 63.33 | Low : | 42.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed below upper band by 17.6%. Bollinger Bands are 20.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.53 - 49.68 | 49.68 - 49.84 |
| Low: | 48.35 - 48.53 | 48.53 - 48.73 |
| Close: | 48.93 - 49.2 | 49.2 - 49.51 |
Sun, 30 Nov 2025
Edgewood Management LLC Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Sun, 30 Nov 2025
Bristol Myers Squibb Company $BMY Holdings Trimmed by Financial Advocates Investment Management - MarketBeat
Sun, 30 Nov 2025
Bristol Myers Squibb (BMY) Is Up 6.4% After EU Approves Breyanzi for Mantle Cell Lymphoma - simplywall.st
Thu, 27 Nov 2025
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth? - Yahoo Finance
Thu, 27 Nov 2025
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Insider Monkey
Thu, 27 Nov 2025
Bristol-Myers Squibb Stock On Fire: Up 7.6% With 5-Day Winning Streak - Trefis
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 2,030 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 82.2 (%) |
| Shares Short | 32,070 (K) |
| Shares Short P.Month | 26,340 (K) |
| EPS | 2.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.1 |
| Profit Margin | 12.5 % |
| Operating Margin | 31.5 % |
| Return on Assets (ttm) | 9.3 % |
| Return on Equity (ttm) | 33.7 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 17.22 |
| Sales Per Share | 23.54 |
| EBITDA (p.s.) | 9.42 |
| Qtrly Earnings Growth | 80.9 % |
| Operating Cash Flow | 16,620 (M) |
| Levered Free Cash Flow | 14,720 (M) |
| PE Ratio | 16.56 |
| PEG Ratio | 0 |
| Price to Book value | 5.4 |
| Price to Sales | 2.08 |
| Price to Cash Flow | 6.03 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 1.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|